(Q35678997)

9 August 2017

1 reference

title

Changing strategies for the management of invasive fungal infections (English)

1 reference

invasive fungal infections

9 August 2017

main subject

1 reference

Robert P Rapp

1

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

24

1 reference

9 August 2017

issue

2 Pt 2

1 reference

9 August 2017

page(s)

4S-28S; quiz 29S-32S

1 reference

Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Recent trends in the epidemiology of invasive mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Candida krusei fungemia. An escalating serious infection in immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Should vascular catheters be removed from all patients with candidemia? An evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Zygomycetes in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Enteral fluconazole is well absorbed in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Fungal infections in patients with solid tumors treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Persistent fever in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Antifungal agents. Part II. The azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.3.4S.33151

10.1592/PHCO.24.3.4S.33151

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference